The objective of the study was to explore the effect of Oxyjun™ on the cardiovascular function of overweight people by reducing obesity induced systemic inflammation. Males aged between 18 - 35 years and body mass index of 25 - 34.9 kg/m2 were recruited in the study. Participants were randomized on baseline visit in two groups to receive either single dose of 400 mg of Oxyjun™ and placebo (for 8-weeks. Participants were  evaluate for obesity related inflammation and quality of life using the change in neutrophil lymphocyte ratio (NLR), high density lipoprotein (HDL-c) and 36 items short form survey (SF-36). NLR was reduced by 0.71 in the Oxyjun™ group and by 0.42 in the placebo group. Within group comparison was significant for Oxyjun™ when compared from baseline (p<0.001) and reduction of NLR in Oxyjun™ group was more than 1.5 times higher than that of placebo. HDL-c levels were improved in the Oxyjun™ group with an increase of 4.04 mg/dL whereas, HDL-c was reduced in the placebo group by 1.22 mg/dL; p=0.09. Further, SF-36 health concepts of fatigue, mental health, and social function showed significant improvement and also the pain scores were improved. No adverse or serious adverse events were reported for the Oxyjun™ as well as the placebo group during the study. Oxyjun™ reduced the NLR of participants demonstrating its potential for lowering adipose tissue induced inflammation. Further, increased HDL levels in Oxyjun™ group can assist in promoting cardiovascular fitness and prevent the risk of future cardiovascular events.

No abstract